AngioDynamics Beats Q4 Estimates Despite Wider Year-Over-Year Loss

Key Facts

As investors scrutinize the healthcare sector for signs of operational recovery, AngioDynamics reported fiscal fourth-quarter financial results that surpassed market expectations. The company posted a quarterly loss of $0.07 per share, outperforming the Zacks Consensus Estimate which had anticipated a wider loss of $0.11. Furthermore, the company exceeded revenue estimates for the period, signaling robust demand for its medical technology portfolio despite broader economic headwinds.

While the results beat consensus estimates, they revealed a widening loss compared to the $0.03 per share loss recorded in the same quarter last year. This performance reflects ongoing cost pressures within the medical device industry; for context, per market data, peers like Boston Scientific have also navigated rising operational expenses, highlighting a sector-wide challenge in maintaining profit margins amid inflationary environments.

According to market data, ANGO shares stood at $12.79 (at close July 10, 2026), having traded between a day low of $12.55 and a high of $12.94. Looking ahead, investors will monitor the stock's ability to maintain its current levels following the July 8 release of the FOMC Minutes, which serves as a broader catalyst for risk sentiment in small-cap healthcare stocks.